The vaccine was originally developed by Biotechnology General.
NasVax Ltd. (TASE: NSVX) has signed a cooperation agreement with SciGen Ltd. of Singapore to jointly develop and commercialize a vaccine against hepatitis B. The companies plan to develop a nasally delivered vaccine, instead of the current injected vaccines.
The vaccine will combine the antigen developed by SciGen and NasVax's adjuvant agents, which enhance the response of the body's immune system to vaccines. The companies will split the product's development costs and revenue.
The vaccine was originally developed by Israeli pharmaceutical company Biotechnology General Ltd., and SciGen's factory in Rehovot is one facility that currently produces it.
Under the agreement, the Phase I and IIa clinical trials of the new vaccine will be conducted in Israel to test its safety and effectiveness on 140 volunteers at Hadassah Medical Organization. The trials are due to begin in 2008.
Published by Globes [online], Israel business news - www.globes-online.com - on December 9, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007